Head and Neck Cancer (HNC) Market Report 2026

The head and neck cancer (hnc) market size has grown strongly in recent years. It will grow from $2.16 billion in 2025 to $2.33 billion in 2026 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increasing prevalence of tobacco and alcohol use, rising incidence of hpv-related cancers, expansion of oncology treatment infrastructure, improved diagnostic capabilities, growing awareness of head and neck cancers.

The head and neck cancer (hnc) market size is expected to see strong growth in the next few years. It will grow to $3.12 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to increasing investments in precision oncology research, rising demand for minimally invasive treatments, expansion of immunotherapy pipelines, growing use of AI-assisted diagnostics, increasing focus on personalized cancer care. Major trends in the forecast period include increasing adoption of targeted and immunotherapy treatments, rising use of advanced diagnostic imaging techniques, growing focus on early cancer detection, expansion of multimodal treatment approaches, enhanced integration of precision oncology.

The rising incidence of cigarette smoking is expected to propel the growth of the head and neck cancer (HNC) market in the coming years. Cigarette smoking involves inhaling and exhaling smoke from burning tobacco and is widely associated with addiction and serious health risks. The increase in smoking rates is commonly driven by factors such as stress, social influences, aggressive marketing strategies, and the easy availability of tobacco products. Therapeutics for head and neck cancer help counteract the harmful effects of cigarette smoking by targeting tobacco-induced molecular changes and treating cancers associated with smoking, while also underscoring the importance of reducing exposure to smoking-related carcinogens to improve treatment outcomes. For example, in October 2024, the European Respiratory Society (ERS), a Switzerland-based non-profit organization, reported findings from a study on youth smoking trends showing a sharp increase in smoking prevalence, with 22.5% of respondents smoking in 2022 compared to 40.1% in 2024. Therefore, the increasing prevalence of cigarette smoking is driving the expansion of the head and neck cancer (HNC) market.

Companies operating in the head and neck cancer (HNC) market are increasingly focused on developing advanced therapies such as immuno-oncology drugs to improve treatment effectiveness, enhance patient survival rates, and address unmet clinical needs associated with complex and advanced cancers. Immuno-oncology drugs are therapies that leverage the body’s immune system to identify and destroy cancer cells and include approaches such as checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines. For instance, in November 2024, Dr. Reddy's Laboratories, an India-based pharmaceutical company, launched toripalimab, an immuno-oncology drug for adult patients with a rare form of head and neck cancer originating in the nasopharynx, the upper region of the throat. Marketed under the brand name Zytorvi, the drug is intended for the treatment of recurrent or metastatic nasopharyngeal carcinoma and has demonstrated a 48% reduction in the risk of disease progression or death when used alongside standard chemotherapy agents gemcitabine and cisplatin.

In September 2023, Coherus BioSciences, a US-based biopharmaceutical company, acquired Surface Oncology Inc. (SURF) for an undisclosed amount. Through this acquisition, Coherus aimed to strengthen its immuno-oncology portfolio by incorporating Surface Oncology’s pipeline of promising drug candidates, including SRF114 and SRF388, which are under development for the treatment of multiple cancer types, including head and neck cancer. This move supports Coherus’ efforts to enhance its competitive position in the oncology market and expand its immunotherapy offerings. Surface Oncology Inc. is a US-based clinical-stage immuno-oncology company focused on developing novel cancer therapies.

Major companies operating in the head and neck cancer (hnc) market are Pfizer Inc., Siemens Healthcare Private Limited, F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Bayer Healthcare AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Koninklijke Philips N.V., Boehringer Ingelheim, Fresenius Kabi AG, Incyte Corporation, Exelixis Inc., Astellas Pharma Inc., Rakuten Medical Inc., Merus N.V.

North America was the largest region in the head and neck cancer (HNC) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the head and neck cancer (hnc) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the head and neck cancer (hnc) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the head and neck cancer market by increasing costs of imported oncology drugs, diagnostic imaging equipment, surgical instruments, and radiotherapy systems. Hospitals and specialty cancer centers in North America and Europe are most affected due to reliance on imported therapeutics and high-end medical devices, while Asia-Pacific faces higher treatment equipment costs. These tariffs are increasing overall treatment expenses and procurement timelines. However, they are also encouraging domestic pharmaceutical manufacturing, regional clinical research, and localized production of oncology equipment.

The head and neck cancer (hnc) market research report is one of a series of new reports that provides head and neck cancer (hnc) market statistics, including head and neck cancer (hnc) industry global market size, regional shares, competitors with a head and neck cancer (hnc) market share, detailed head and neck cancer (hnc) market segments, market trends and opportunities, and any further data you may need to thrive in the head and neck cancer (hnc) industry. This head and neck cancer (hnc) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Head and neck cancer (HNC) refers to a group of epithelial cancers that originate in the head and neck region, including the oral cavity, pharynx, larynx, nasal cavity, and salivary glands. Most cases are squamous cell carcinomas, with major risk factors such as tobacco use, alcohol consumption, and infection with human papillomavirus (HPV).

The main types of head and neck cancer (HNC) include laryngeal cancer, pharyngeal cancer, salivary gland cancer, lip and oral cavity cancer, nasopharyngeal cancer, and others. Laryngeal cancer arises in the larynx, commonly known as the voice box, which plays a key role in sound production, breathing, and swallowing. Treatment options include chemotherapy, surgery, radiation therapy, targeted therapy, and others. Diagnostic methods include biopsy screening tests, blood tests, dental examinations, imaging, and endoscopy. These treatments and diagnostic services are distributed through channels such as hospital pharmacies, retail pharmacies, and e-commerce platforms and are utilized by end users including hospitals, specialty clinics, ambulatory surgical centers, and others.

The head and neck cancer (HNC) market consists of revenues earned by providing services such as systemic therapy, photodynamic therapy (PDT) and combined modality therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The head and neck cancer (HNC) market also includes sales of targeted therapy drugs, and combination therapy products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.